Possibilities of differential diagnosis of uterine leiomyosarcoma

Cover Page

Cite item

Full Text

Abstract

Uterine leiomyosarcoma is a rare malignant neoplasm consisting of smooth muscle cells, characterized by an aggressive course and poor prognosis.

Differential diagnosis of uterine leiomyosarcoma is challenging due to the nonspecificity and low severity of symptoms, particularly in the early stages. Patients with uterine leiomyosarcoma commonly present with complaints in of pelvic pain, abnormal uterine bleeding, and symptoms of compression of nearby organs. The same clinical symptoms are characteristics of patients with uterine leiomyomas.

Leiomyosarcoma is often detected after histologic examination of material obtained during surgery for uterine myoma. At the same time, preoperative verification of the malignant nature of the neoplasm is crucial in determining the optimal tactics of surgical treatment. For instance, the use of organ-preserving techniques and morcellation in the treatment of presumed uterine leiomyoma may result in the dissemination of tumor cells and significantly worsen the prognosis in patients with undiagnosed leiomyosarcoma.

This review discusses existing methods of preoperative diagnosis of uterine leiomyosarcoma, their efficacy, as well as the possibilities of application in clinical practice.

About the authors

Elena A. Sosnova

I.M. Sechenov First Moscow State Medical University

Email: sosnova-elena@inbox.ru
ORCID iD: 0000-0002-1732-6870
SPIN-code: 6313-9959

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Arina A. Kordys

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: arina.kordys@yandex.ru
ORCID iD: 0009-0003-9170-706X

Student

Russian Federation, Moscow

References

  1. Multinu F, Casarin J, Tortorella L, et al. Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study. Am J Obstet Gynecol. 2019;220(2):179.e1–179.e10. doi: 10.1016/j.ajog.2018.11.1086
  2. Skorstad M, Kent A, Lieng M. Preoperative evaluation in women with uterine leiomyosarcoma. A nationwide cohort study. Acta Obstet Gynecol Scand. 2016;95(11):1228–1234. doi: 10.1111/aogs.13008
  3. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71(4 Suppl.):1702–1709. doi: 10.1002/cncr.2820710440
  4. Ul’rikh EA. Features of the treatment of uterine sarcoma. Practical Oncology. 2013;14(2):127–134. (In Russ).
  5. Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynecol Obstet. 2018;143 Suppl. 2:51–58. doi: 10.1002/ijgo.12613
  6. Chantasartrassamee P, Kongsawatvorakul C, Rermluk N, et al. Preoperative clinical characteristics between uterine sarcoma and leiomyoma in patients with uterine mass, a case-control study. Eur J Obstet Gynecol Reprod Biol. 2022;270:176–180. doi: 10.1016/j.ejogrb.2022.01.013
  7. Chen I, Firth B, Hopkins L, et al. Clinical Characteristics Differentiating Uterine Sarcoma and Fibroids. JSLS. 2018;22(1):e2017.00066. doi: 10.4293/JSLS.2017.00066
  8. Zhang G, Yu X, Zhu L, et al. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer. 2020;20(1):514. doi: 10.1186/s12885-020-07003-z
  9. Nagai T, Takai Y, Akahori T, et al. Highly improved accuracy of the revised PREoperative sarcoma score (rPRESS) in the decision of performing surgery for patients presenting with a uterine mass. Springerplus. 2015;4:520. doi: 10.1186/s40064-015-1318-7
  10. Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer. 2002;12(4):354–361. doi: 10.1046/j.1525-1438.2002.01086.x
  11. Cho H-Y, Kim K, Kim Y-B, No JH. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. J Obstet Gynaecol Res. 2015;42(3):313–318. doi: 10.1111/jog.12915
  12. Exacoustos C, Romanini ME, Amadio A, et al. Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma? J Clin Ultrasound. 2007;35(8):449–457. doi: 10.1002/jcu.20386
  13. Ludovisi M, Moro F, Pasciuto T, et al. Imaging in gynecological disease (15): Clinical and ultrasound characteristics of uterine sarcoma. Ultrasound Obstet Gynecol. 2019;54(5):676–687. doi: 10.1002/uog.20270
  14. Sun S, Bonaffini PA, Nougaret S, et al. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging. 2019;100(10):619–634. doi: 10.1016/j.diii.2019.07.007
  15. Stolyarova IV, Yakovleva EK, Sharakova VV. Evaluation of diagnostic effectiveness of the method of diffusion-weighted MR-images in diagnosis of pathology of the uterine body. Problems in Oncology. 2015;61(6):986–993. (In Russ).
  16. Camponovo C, Neumann S, Zosso L, Mueller MD, Raio L. Sonographic and Magnetic Resonance Characteristics of Gynecological Sarcoma. Diagnostics (Basel). 2023;13(7):1223. doi: 10.3390/diagnostics13071223
  17. Namimoto T, Yamashita Y, Awai K, et al. Combined use of T2-weighted and diffusion-weighted 3-T MR imaging for differentiating uterine sarcomas from benign leiomyomas. Eur Radiol. 2009;19(11):2756–2764. doi: 10.1007/s00330-009-1471-x
  18. Sadeghi R, Zakavi SR, Hasanzadeh M, et al. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature. Int J Gynecol Cancer. 2013;23(8):1349–1356. doi: 10.1097/IGC.0b013e3182a20e18
  19. Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol. 2008;110(1):43–48. doi: 10.1016/j.ygyno.2008.02.026
  20. Hinchcliff EM, Esselen KM, Watkins JC, et al. The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma. J Minim Invasive Gynecol. 2016;23(4):567–572. doi: 10.1016/j.jmig.2016.01.022
  21. Stukan M, Rutkowski P, Smadja J, Bonvalot S. Ultrasound-Guided Trans-Uterine Cavity Core Needle Biopsy of Uterine Myometrial Tumors to Differentiate Sarcoma from a Benign Lesion-Description of the Method and Review of the Literature. Diagnostics (Basel). 2022;12(6):1348. doi: 10.3390/diagnostics12061348
  22. Yoshida C, Ichimura T, Kawamura N, et al. A scoring system for histopathologic and immunohistochemical evaluations of uterine leiomyosarcomas. Oncol Rep. 2009;22(4):725–731. doi: 10.3892/or_00000493
  23. Bogani G, Cliby WA, Aletti GD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol. 2015;137(1):167–172. doi: 10.1016/j.ygyno.2014.11.011
  24. Bretthauer M, Goderstad JM, Løberg M, et al. Uterine morcellation and survival in uterine sarcomas. Eur J Cancer. 2018;101:62–68. doi: 10.1016/j.ejca.2018.06.007

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).